GAIA-102 interim data in pediatric neuroblastoma to be presented at the 67th Annual Meeting of the Japanese Society of Pediatric Hematology/Oncology

Interim results from the clinical trial of GAIA-102 will be presented at the 67th Annual Meeting of the Japanese Society of Pediatric Hematology/Oncology (President: Tatsuro Tajiri, Professor of the Department of Pediatric Surgery, Faculty of Medical Sciences, Kyushu University).

This presentation will introduce interim data on the safety and efficacy from Cohort B (combination cohort) of the ongoing clinical trial for patients with refractory/relapsed pediatric neuroblastoma. Neuroblastoma is an intractable disease with a significant unmet medical need.

Presentation Information:

Title: Safety and Efficacy of CD3-Negative NK-like Cells (GAIA-102) in Refractory or Relapsed Neuroblastoma: Interim Report from Combination Cohort
Author: Kenta Ishimoto, Naonori Kawakubo, Yui Harada, Yosuke Morodomi, Yoshiki Yamaguchi, Junnosuke Maniwa, Utako Oba, Toshiharu Matsuura, Shouichi Ohga, Yoshikazu Yonemitsu, Tatsuro Tajiri
Session: Best Paper Session (Presented in English)
Scheduled for: November 19, 2025, 11:10~12:10, Room 2, Fukuoka International Congress Center

About the Japanese Society of Pediatric Hematology/Oncology:

The Japanese Society of Pediatric Hematology/Oncology was formed in 2011 as a merger of two previous organizations: the Japanese Society of Pediatric Hematology (established in 1960) and the Japanese Society of Pediatric Oncology (established in 1985). The society is an academic organization aiming to contribute to the advancement of medical care in pediatric hematology/oncology in Japan by promoting academic activities, raising social awareness, and conducting research and accreditation of specialists in the field of pediatric hematology/oncology.

The 67th Annual Meeting of the Japanese Society of Pediatric Hematology/Oncology

Share on